Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

DMTs slow the progression of multiple sclerosis and reduce relapse severity. Starting DMTs soon after diagnosis can help ...

MS patients have increased risks of developing other autoimmune diseases, necessitating careful treatment planning to balance efficacy and risk. Dimethyl fumarate, anti-CD20 antibodies, and ozanimod ...

Panelists discuss how academic centers can use telehealth programs like Project ECHO to train community neurologists and ensure consistent, evidence-based MS care across diverse geographic regions.

Advances in diagnostics and disease-modifying therapies have significantly expanded treatment options for MS over the past 2 ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton’s tyrosine kinase inhibitor (a group of drugs originally developed to treat lymphomas and related blood disorders) ...

Multiple Sclerosis (MS) is a long-term disease where the immune system mistakenly attacks the protective layer around nerve cells, known as the myelin sheath. This leads to nerve damage and worsening ...

The University of Virginia’s (UVA) health system has become one of the first in the country to administer a groundbreaking FDA-approved drug, Ocrevus Zunovo, to patients with progressive types of ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Two key symptoms that can arise soon after a diagnosis of multiple sclerosis (MS) could predict how swiftly the illness will progress and suggest best treatment options, new research shows. The two ...

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...